Livzon Mabpharm of Zhuhai , Guangdong Provence , out-licensed its clinical stage PD-1 to Bright Peak Therapeutics of San Diego to develop PD-1 targeted immunocytokines. The PD-1 ICs will contain optimized cytokine payloads developed by Bright Peak  and conjugated to the PD-1 to treat a variety of cancers. Bright Peak will own global rights to the PD-1 ICs, while Livzon will have first negotiation rights in China . Bright Peak will be responsible for all development activities. Livzon will receive an upfront payment plus milestones and royalties. More details.... Share this with colleagues: // //